AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8290902 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpirome 2 g bid
Number of subjects: 865
Study 8290902 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime 2 g bid
Number of subjects: 865
Study 8290902 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime 2 g tid
Number of subjects: 865
Study 8290902 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 1 g bid
Number of subjects: 865
Study 8290902 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpirome
Number of subjects: 865
Study 8290902 — intervention group
Group type: COMPARATOR
Intervention: Comparators
Number of subjects: 865
Study 3326634 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol, 10 mg twice daily
Number of subjects: 10
Study 3326634 — intervention group
Group type: COMPARATOR
Intervention: Propranolol, 80 mg three times daily
Number of subjects: 10
Study 25393089 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic steroid therapy
Number of subjects: 80
Study 25393089 — intervention group
Group type: COMPARATOR
Intervention: Thermal therapy (sulphurous water insufflation)
Number of subjects: 80
Study 24796484 — intervention group
Group type: EXPERIMENTAL
Intervention: sunitinib
Number of subjects: 321
Study 23611571 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg INFS (Treatment A)
Number of subjects: 20
Study 23611571 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 μg INFS (Treatment B)
Number of subjects: 20
Study 23611571 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 μg INFS (Treatment C)
Number of subjects: 20
Study 21044931 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-absorbable interrupted sutures (NA)
Number of subjects: 198
Study 21044931 — intervention group
Group type: COMPARATOR
Intervention: Absorbable continuous sutures (A)
Number of subjects: 198
Study 18223286 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8-depleted peripheral blood stem cells
Number of subjects: 50
Study 18223286 — intervention group
Group type: COMPARATOR
Intervention: Non-manipulated peripheral blood stem cells
Number of subjects: 50
Study 18223286 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8-depleted and non-manipulated peripheral blood stem cells
Number of subjects: 50
Study 18223286 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with high sjTREC concentration
Number of subjects: 50
Study 16306217 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat stress
Number of subjects: 17
Study 16306217 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling
Number of subjects: 17
Study 16306217 — intervention group
Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 17
Study 14620118 — intervention group
Group type: EXPERIMENTAL
Intervention: Crowned teeth
Number of subjects: 11
Study 14620118 — intervention group
Group type: COMPARATOR
Intervention: Control teeth (no restorations)
Number of subjects: 11
Study 10876973 — intervention group
Group type: EXPERIMENTAL
Intervention: Product A (Decortil lipocrema IDI Farmaceutici)
Number of subjects: 30
Study 10876973 — intervention group
Group type: EXPERIMENTAL
Intervention: Product B (Decortil crema, IDI Farmaceutici)
Number of subjects: 30
Study 10876973 — intervention group
Group type: COMPARATOR
Intervention: Product C (Lichtena AI crema UCB Pharma)
Number of subjects: 30
Study 8701045 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate 600 mg followed by mefloquine 500 mg
Number of subjects: 153
Study 8701045 — intervention group
Group type: COMPARATOR
Intervention: mefloquine 1000 mg
Number of subjects: 153
Study 8701045 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of artesunate and mefloquine
Number of subjects: 153
Study 8701045 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate alone
Number of subjects: 153
Study 1735009 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (DDP) 37.5 mg/m2 (regimens A and B) or 75 mg/m2 (regimens C and D) + Hexamethylmelamine (HMM) 200 mg/m2 orally daily on days 8‐21
Number of subjects: 248
Study 1735009 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (DDP) + Hexamethylmelamine (HMM)
Number of subjects: 248
Study 1735009 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine 300 mg/m2 orally on Days 1‐21 (regimens B and D)
Number of subjects: 248
Study 6547795 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (specific type not mentioned)
Number of subjects: 0
Study 6547795 — intervention group
Group type: COMPARATOR
Intervention: Non-treated control group
Number of subjects: 0
Study 31292932 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive task (counting backward from a randomly chosen three-digit number)
Number of subjects: 15
Study 31292932 — intervention group
Group type: EXPERIMENTAL
Intervention: Light finger touch contact
Number of subjects: 15
Study 31292932 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision available vs. not available
Number of subjects: 15
Study 31292932 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger touch and cognitive task simultaneously
Number of subjects: 15
Study 30782764 — intervention group
Group type: EXPERIMENTAL
Intervention: ToyBox obesity prevention intervention; details on dosage and duration not available
Number of subjects: 0
Study 30782764 — intervention group
Group type: COMPARATOR
Intervention: Control group; details not specified
Number of subjects: 0
Study 28681171 — intervention group
Group type: EXPERIMENTAL
Intervention: R/D/E (ridaforolimus 10 mg QD 5 ×/week, dalotuzumab 10 mg/kg/week, exemestane 25 mg/day)
Number of subjects: 80
Study 28681171 — intervention group
Group type: COMPARATOR
Intervention: R/E (ridaforolimus 30 mg QD 5 ×/week, exemestane 25 mg/day)
Number of subjects: 80
Study 28681171 — intervention group
Group type: COMPARATOR
Intervention: R/E
Number of subjects: 80
Study 28681171 — intervention group
Group type: EXPERIMENTAL
Intervention: R/D/E
Number of subjects: 80
Study 26426556 — intervention group
Group type: EXPERIMENTAL
Intervention: Laerdal Skill Reporter (LSR)
Number of subjects: 15
Study 26426556 — intervention group
Group type: COMPARATOR
Intervention: Philips MRx Q-CPR
Number of subjects: 15
Study 23422465 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate 20-week biweekly gym training programme
Number of subjects: 32
Study 23422465 — intervention group
Group type: COMPARATOR
Intervention: Delayed 10-week gym training programme starting 10 weeks later
Number of subjects: 32
Study 21555815 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug Conservation (DC) arm
Number of subjects: 2248
Study 21555815 — intervention group
Group type: COMPARATOR
Intervention: Viral Suppression (VS) arm
Number of subjects: 2248
Study 21555815 — intervention group
Group type: EXPERIMENTAL
Intervention: Currently anaemic patients
Number of subjects: 2248
Study 19617601 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous left ventricular assist devices (LVADs)
Number of subjects: 2
Study 19617601 — intervention group
Group type: COMPARATOR
Intervention: TandemHeart
Number of subjects: 2
Study 18236200 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced Retrieval (SR) training
Number of subjects: 38
Study 18236200 — intervention group
Group type: COMPARATOR
Intervention: Didactic strategy instruction (SI)
Number of subjects: 38
Study 15169576 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of r-hFSH and r-hLH (2:1 ratio)
Number of subjects: 231
Study 15169576 — intervention group
Group type: COMPARATOR
Intervention: r-hFSH alone
Number of subjects: 231
Study 12177098 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant 250 mg once monthly
Number of subjects: 400
Study 12177098 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole 1 mg daily
Number of subjects: 400
Study 9875582 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-drug oral regimen (Rifampin 10 mg/kg daily, Ciprofloxacin 500 mg twice daily, Clofazimine 100 mg every day, Ethambutol 15 mg/kg daily) + Amikacin 10 mg/kg intravenously or intramuscularly 5 days weekly for the first 4 weeks
Number of subjects: 74
Study 9875582 — intervention group
Group type: COMPARATOR
Intervention: Four-drug oral regimen (Rifampin 10 mg/kg daily, Ciprofloxacin 500 mg twice daily, Clofazimine 100 mg every day, Ethambutol 15 mg/kg daily)
Number of subjects: 74
Study 7597661 — intervention group
Group type: EXPERIMENTAL
Intervention: Eformoterol 24 micrograms twice daily
Number of subjects: 16
Study 7597661 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily
Number of subjects: 16
Study 2348454 — intervention group
Group type: EXPERIMENTAL
Intervention: Whirlpool baths
Number of subjects: 40
Study 2348454 — intervention group
Group type: COMPARATOR
Intervention: Warm baths
Number of subjects: 40
Study 88330 — intervention group
Group type: EXPERIMENTAL
Intervention: Checkerboard pattern displacement (red, green, blue)
Number of subjects: 0
Study 88330 — intervention group
Group type: EXPERIMENTAL
Intervention: Colour stimulation (red, green, blue)
Number of subjects: 0
Study 88330 — intervention group
Group type: EXPERIMENTAL
Intervention: Luminance measurement
Number of subjects: 0
Study 6357209 — intervention group
Group type: EXPERIMENTAL
Intervention: suprofen 400 mg
Number of subjects: 196
Study 6357209 — intervention group
Group type: EXPERIMENTAL
Intervention: suprofen 200 mg
Number of subjects: 196
Study 6357209 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA 650 mg + codeine 60 mg
Number of subjects: 196
Study 6357209 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA 650 mg
Number of subjects: 196
Study 6357209 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 196
Study 31078486 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT-HIP intervention (multicomponent cognitive behavioral intervention conducted by physiotherapists)
Number of subjects: 78
Study 31078486 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT-HIP intervention
Number of subjects: 78
Study 31078486 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 78
Study 27530927 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cholecystectomy
Number of subjects: 72
Study 27530927 — intervention group
Group type: COMPARATOR
Intervention: Delayed cholecystectomy
Number of subjects: 72
Study 27428506 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod
Number of subjects: 30
Study 27428506 — intervention group
Group type: COMPARATOR
Intervention: Laser vaporisation
Number of subjects: 30
Study 27428506 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 30
Study 24639418 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of sunscreen
Number of subjects: 2
Study 24639418 — intervention group
Group type: COMPARATOR
Intervention: High sun exposure (Monegasque)
Number of subjects: 2
Study 24639418 — intervention group
Group type: COMPARATOR
Intervention: Low sun exposure (Berlin)
Number of subjects: 2
Study 21278165 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention (10-min exposure to relaxing music through headphones)
Number of subjects: 140
Study 21278165 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music intervention)
Number of subjects: 140
Study 20194044 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (CTM) 48 mg/kg/day divided into two doses for 1 month
Number of subjects: 46
Study 20194044 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 1 month
Number of subjects: 46
Study 19089226 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin adhesive derived from snake venom
Number of subjects: 15
Study 19089226 — intervention group
Group type: COMPARATOR
Intervention: Sutured grafts (control group)
Number of subjects: 15
Study 14685867 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum (BC) 60 g.day(‐1)
Number of subjects: 13
Study 11395670 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg
Number of subjects: 461
Study 11395670 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg
Number of subjects: 461
Study 9262268 — intervention group
Group type: EXPERIMENTAL
Intervention: HCG (5000 IU) after Dexamethasone administration
Number of subjects: 23
Study 8498665 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ropivacaine
Number of subjects: 44
Study 8498665 — intervention group
Group type: COMPARATOR
Intervention: 0.75% bupivacaine
Number of subjects: 44
Study 3434739 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% hyperbaric lignocaine
Number of subjects: 20
Study 3434739 — intervention group
Group type: COMPARATOR
Intervention: 0.5% hyperbaric bupivacaine
Number of subjects: 20
Study 3434739 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 20
Study 28926636 — intervention group
Group type: EXPERIMENTAL
Intervention: Per-unit dispensing of antibiotics (experimental group)
Number of subjects: 1185
Study 28926636 — intervention group
Group type: COMPARATOR
Intervention: Traditional pre-packed boxes of antibiotics (control group)
Number of subjects: 1185
Study 27188987 — intervention group
Group type: COMPARATOR
Intervention: Low AKG content (LAC, 10 mg AKGs)
Number of subjects: 26
Study 27188987 — intervention group
Group type: EXPERIMENTAL
Intervention: High AKG content (HAC, 20 mg AKGs)
Number of subjects: 26
Study 25202816 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI < 18.5 kg/m2
Number of subjects: 2620
Study 25202816 — intervention group
Group type: COMPARATOR
Intervention: BMI 18.5-24.9 kg/m2
Number of subjects: 2620
Study 25202816 — intervention group
Group type: COMPARATOR
Intervention: BMI ≥ 18.5 kg/m2
Number of subjects: 2620
Study 21987579 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery after trabeculectomy
Number of subjects: 235
Study 21987579 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery performed 6 months after trabeculectomy
Number of subjects: 235
Study 21987579 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery performed 1 year after trabeculectomy
Number of subjects: 235
Study 21987579 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery performed 2 years after trabeculectomy
Number of subjects: 235
Study 19161045 — intervention group
Group type: EXPERIMENTAL
Intervention: ERr 731
Number of subjects: 112
Study 19161045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 17211062 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver fiber-containing compression stockings
Number of subjects: 10
Study 17211062 — intervention group
Group type: COMPARATOR
Intervention: Regular hosiery
Number of subjects: 10
Study 15882526 — intervention group
Group type: EXPERIMENTAL
Intervention: dTpa-IPV vaccine
Number of subjects: 806
Study 15882526 — intervention group
Group type: COMPARATOR
Intervention: dTpa+IPV vaccine
Number of subjects: 806
Study 15882526 — intervention group
Group type: COMPARATOR
Intervention: Td-IPV vaccine
Number of subjects: 806
Study 11211195 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg (500 mg/kg/day for 7 days)
Number of subjects: 30
Study 11211195 — intervention group
Group type: COMPARATOR
Intervention: Monoclonal anti-CD3 (OKT3, 5 mg/day for 14 days)
Number of subjects: 30
Study 11211195 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg
Number of subjects: 30
Study 11211195 — intervention group
Group type: COMPARATOR
Intervention: OKT3
Number of subjects: 30
Study 10083972 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine (0.5%) with adrenaline (1:200,000)
Number of subjects: 100
Study 10083972 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine (0.5%)
Number of subjects: 100
Study 10083972 — intervention group
Group type: EXPERIMENTAL
Intervention: normal saline with adrenaline (1:200,000)
Number of subjects: 100
Study 10083972 — intervention group
Group type: EXPERIMENTAL
Intervention: normal saline
Number of subjects: 100
Study 10083972 — intervention group
Group type: COMPARATOR
Intervention: no infiltration (control group)
Number of subjects: 100
Study 7522124 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy
Number of subjects: 0
Study 7522124 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined postoperative radiation and chemotherapy
Number of subjects: 0
Study 3406681 — intervention group
Group type: EXPERIMENTAL
Intervention: Intellectual Function Training (IFT) plus a regular rehabilitation programme (R) (n = 15)
Number of subjects: 67
Study 3406681 — intervention group
Group type: EXPERIMENTAL
Intervention: Intellectual Housework Training (IHT) plus R (n = 19)
Number of subjects: 67
Study 3406681 — intervention group
Group type: EXPERIMENTAL
Intervention: IFT + IHT + R (n = 15)
Number of subjects: 67
Study 3406681 — intervention group
Group type: COMPARATOR
Intervention: Regular rehabilitation only (R) (n = 18)
Number of subjects: 67
Study 3406681 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalization gains in 4/5 'theoretical' intellectual functional areas assessed with IFA
Number of subjects: 67
Study 3406681 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalization gains in 3/7 'practical' intellectual functional areas assessed with IHA
Number of subjects: 67
Study 31408192 — intervention group
Group type: EXPERIMENTAL
Intervention: Families on Track (FOT) intervention
Number of subjects: 30
Study 31408192 — intervention group
Group type: COMPARATOR
Intervention: Active comparison group
Number of subjects: 30
Study 28803087 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT)
Number of subjects: 22
Study 28803087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 26068323 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg.kg‐1)
Number of subjects: 14
Study 26068323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 25605189 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous flurbiprofen axetil and opioids
Number of subjects: 120
Study 25605189 — intervention group
Group type: COMPARATOR
Intervention: Morphine sulfate sustained-release tablets
Number of subjects: 120
Study 22066559 — intervention group
Group type: EXPERIMENTAL
Intervention: PFC prosthesis
Number of subjects: 82
Study 22066559 — intervention group
Group type: COMPARATOR
Intervention: CKS prosthesis
Number of subjects: 82
Study 18976733 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate circumcision
Number of subjects: 1608
Study 18976733 — intervention group
Group type: COMPARATOR
Intervention: Delayed circumcision (control)
Number of subjects: 1608
Study 17705186 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine therapy
Number of subjects: 486
Study 15172863 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mL 1% lidocaine infusion
Number of subjects: 80
Study 15172863 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 80
Study 15172863 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 minutes after lidocaine infusion
Number of subjects: 80
Study 11508185 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT)
Number of subjects: 27
Study 9790153 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.125 mg twice a day
Number of subjects: 64
Study 9790153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 7658064 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhesus rotavirus monovalent reassortant vaccine (10^4 pfu)
Number of subjects: 33
Study 7658064 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent vaccine (10^4 pfu)
Number of subjects: 33
Study 7658064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 2651924 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine, 150 mg nightly
Number of subjects: 140
Study 2651924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 1132949 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg Primperan (20 mg metoclopramide, Lundbeck)
Number of subjects: 45
Study 1132949 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg Metopram (20 mg metoclopramide, Leiras)
Number of subjects: 45
Study 1132949 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (control group)
Number of subjects: 45
Study 31090170 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine (LdT)
Number of subjects: 60
Study 31090170 — intervention group
Group type: COMPARATOR
Intervention: Entecavir (ETV)
Number of subjects: 60
Study 31090170 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LdT and ETV
Number of subjects: 60
Study 30736781 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week RUFIT-NZ intervention
Number of subjects: 96
Study 30736781 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study 28499715 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplements in infancy
Number of subjects: 113
Study 28499715 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum anti‐flagellin IgA concentration at 6 weeks
Number of subjects: 113
Study 26310979 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention (HBI)
Number of subjects: 280
Study 26310979 — intervention group
Group type: COMPARATOR
Intervention: Specialized clinic-based intervention (CBI)
Number of subjects: 280
Study 22749947 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (4 g over 15 minutes followed by 16 g over 24 hours)
Number of subjects: 107
Study 22749947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 20561173 — intervention group
Group type: EXPERIMENTAL
Intervention: Home set-up polysomnography (PSG)
Number of subjects: 30
Study 20561173 — intervention group
Group type: COMPARATOR
Intervention: Laboratory-based PSG
Number of subjects: 30
Study 20561173 — intervention group
Group type: EXPERIMENTAL
Intervention: Home set-up PSG
Number of subjects: 30
Study 19910811 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 50
Study 17317046 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal E2/NETA (25 microg E2 and 125 microg NETA applied every 3-4 days)
Number of subjects: 677
Study 17317046 — intervention group
Group type: COMPARATOR
Intervention: Oral E2/NETA (1 mg E2 and 0.5 mg NETA given daily)
Number of subjects: 677
Study 17317046 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal E2/NETA
Number of subjects: 677
Study 17317046 — intervention group
Group type: COMPARATOR
Intervention: Oral E2/NETA
Number of subjects: 677
Study 15284540 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital ETCO2/Spo2 monitoring during paramedic rapid sequence intubation (RSI) using midazolam and succinylcholine; rocuronium administered after confirmation of tube position.
Number of subjects: 426